X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1246) 1246
Publication (71) 71
Newsletter (33) 33
Book Chapter (16) 16
Book Review (13) 13
Conference Proceeding (2) 2
Book / eBook (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1057) 1057
female (636) 636
thrombocytosis (571) 571
male (552) 552
middle aged (456) 456
adult (408) 408
hematology (363) 363
aged (361) 361
index medicus (357) 357
thrombocytosis - drug therapy (330) 330
oncology (248) 248
platelet count (235) 235
thrombocytosis - complications (183) 183
thrombocytosis - etiology (171) 171
thrombocythemia (161) 161
polycythemia-vera (157) 157
essential thrombocythemia (148) 148
thrombocytosis - blood (125) 125
prognosis (122) 122
aged, 80 and over (120) 120
risk factors (120) 120
thrombosis (120) 120
platelets (116) 116
thrombocytosis - diagnosis (116) 116
myeloproliferative disorders (111) 111
adolescent (110) 110
treatment outcome (107) 107
retrospective studies (105) 105
blood platelets (104) 104
diagnosis (104) 104
care and treatment (103) 103
hydroxyurea (102) 102
thrombocytosis - chemically induced (100) 100
hydroxyurea - therapeutic use (93) 93
drug therapy (92) 92
medicine, general & internal (92) 92
cancer (90) 90
child (87) 87
therapy (87) 87
animals (84) 84
platelet aggregation inhibitors - therapeutic use (83) 83
mutation (81) 81
research (80) 80
leukemia (79) 79
medicine & public health (78) 78
aspirin - therapeutic use (77) 77
myelofibrosis (77) 77
polycythemia vera (77) 77
diagnosis, differential (75) 75
survival (71) 71
antineoplastic agents - therapeutic use (68) 68
thrombocythemia, essential - drug therapy (67) 67
polycythemia vera - drug therapy (66) 66
quinazolines - therapeutic use (66) 66
anemia (64) 64
thrombocytosis - therapy (64) 64
patients (63) 63
anagrelide (62) 62
analysis (60) 60
thrombocytosis - pathology (60) 60
child, preschool (59) 59
hydroxyurea - adverse effects (58) 58
pregnancy (56) 56
surgery (56) 56
time factors (56) 56
disease (55) 55
pediatrics (55) 55
thrombopoietin (55) 55
blood cell count (54) 54
follow-up studies (54) 54
thrombocytosis - genetics (54) 54
aspirin (53) 53
janus kinase 2 - genetics (53) 53
blood (52) 52
complications and side effects (51) 51
myeloproliferative neoplasms (51) 51
tumors (51) 51
health aspects (50) 50
metastasis (49) 49
prospective studies (48) 48
interferon-alpha - therapeutic use (47) 47
thrombocythemia, essential - diagnosis (47) 47
infant (46) 46
abridged index medicus (45) 45
blood platelets - drug effects (45) 45
bone marrow - pathology (45) 45
busulfan - therapeutic use (45) 45
myeloproliferative disorders - drug therapy (45) 45
myeloproliferative disorders - complications (44) 44
thrombosis - etiology (44) 44
pharmacology & pharmacy (42) 42
risk (42) 42
essential thrombocytosis (41) 41
reactive thrombocytosis (40) 40
chemotherapy (39) 39
chronic myelogenous leukemia (39) 39
internal medicine (39) 39
thrombocytopenia (39) 39
chronic myeloproliferative disorders (38) 38
patient outcomes (38) 38
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1182) 1182
French (24) 24
German (17) 17
Japanese (17) 17
Spanish (11) 11
Polish (8) 8
Danish (7) 7
Russian (7) 7
Czech (5) 5
Dutch (5) 5
Italian (5) 5
Chinese (2) 2
Finnish (2) 2
Hebrew (2) 2
Arabic (1) 1
Serbian (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS Medicine, ISSN 1549-1277, 2006, Volume 3, Issue 7, pp. 1140 - 1151
The JAK2V617F allele has recently been identified in patients with polycythemia vera (PV), essential thrombocytosis (ET), and myelofibrosis with myeloid... 
Recombinant Fusion Proteins - adverse effects | Humans | Myeloproliferative Disorders - pathology | Mutation, Missense | Primary Myelofibrosis - pathology | Receptors, Cytokine - physiology | Janus Kinases - physiology | Bone Marrow Transplantation | Hematopoiesis - physiology | Myeloid Cells - drug effects | Transcription, Genetic | Colony-Forming Units Assay | Phosphorylation - drug effects | mRNA Cleavage and Polyadenylation Factors - genetics | Hematologic Neoplasms - physiopathology | Disease Models, Animal | Cells, Cultured - drug effects | Bone Marrow Cells - pathology | Hematopoiesis - genetics | Signal Transduction - genetics | Thrombocytosis - etiology | Sequence Analysis, DNA | Cell Division - drug effects | mRNA Cleavage and Polyadenylation Factors - physiology | Receptor, Platelet-Derived Growth Factor alpha - physiology | Hematologic Neoplasms - drug therapy | Mice | Mice, Inbred BALB C | Myeloid Cells - pathology | Protein Processing, Post-Translational - genetics | Myeloproliferative Disorders - genetics | Oncogene Proteins, Fusion - physiology | STAT Transcription Factors - physiology | Protein Processing, Post-Translational - drug effects | Cells, Cultured - pathology | Bone Marrow Cells - drug effects | Spleen - pathology | Thrombocytosis - pathology | Gene Expression Regulation | Janus Kinases - antagonists & inhibitors | Point Mutation | Megakaryocytes - pathology | Primary Myelofibrosis - genetics | Animals | Oncogene Proteins, Fusion - genetics | Protein Kinase Inhibitors - therapeutic use | Receptor, Platelet-Derived Growth Factor alpha - genetics | Myeloproliferative Disorders - etiology | Signal Transduction - physiology | Protein Kinase Inhibitors - pharmacology | Genetic Vectors | Megakaryocytes - drug effects | Cytokines - pharmacology | Amino Acid Substitution | Thrombocytosis - genetics | Genetic aspects | Myelofibrosis | Research | Hematology | Gene Therapy | Genomics | Genetics | Oncology | Cancer Biology | Hematology (including Blood Transfusion)
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 11/2013, Volume 19, Issue 22, pp. 6230 - 6241
Journal Article
Annals of Hematology, ISSN 0939-5555, 12/2010, Volume 89, Issue 12, pp. 1233 - 1237
Journal Article
Cancer, ISSN 0008-543X, 08/2007, Volume 110, Issue 3, pp. 543 - 550
BACKGROUND. Therapy targeted against the vascular endothelial growth factor (VEGF) pathway is a standard of care for patients with metastatic renal cell... 
prognostic factors | prognostic model | advanced renal cell carcinoma | vascular endothelial growth factor | angiogenesis | Angiogenesis | Prognostic model | Vascular endothelial growth factor | Advanced renal cell carcinoma | Prognostic factors | PROGNOSTIC-FACTORS | LONG-TERM SURVIVAL | TUMOR-SUPPRESSOR GENE | CANCER | INTERFERON-ALPHA | ONCOLOGY | PLATELETS | DISEASE | SUNITINIB | THROMBOCYTOSIS | PROGRESSION | Niacinamide - analogs & derivatives | Prognosis | Prospective Studies | Humans | Middle Aged | Neovascularization, Pathologic | Imidazoles - administration & dosage | Male | Kidney Neoplasms - metabolism | Phenylurea Compounds | Vascular Endothelial Growth Factor A - metabolism | Benzenesulfonates - administration & dosage | Indazoles - administration & dosage | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Indoles - administration & dosage | Bevacizumab | Antibodies, Monoclonal, Humanized | Clinical Trials, Phase III as Topic | Pyrroles - administration & dosage | Female | Carcinoma, Renal Cell - drug therapy | Pyridines - administration & dosage | Carcinoma, Renal Cell - pathology | Survival Rate | Vascular Endothelial Growth Factor A - immunology | Randomized Controlled Trials as Topic | Carcinoma, Renal Cell - metabolism | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Kidney Neoplasms - pathology | Kidney Neoplasms - drug therapy | Clinical Trials, Phase II as Topic | Patient outcomes | Physiological aspects | Carcinoma, Renal cell | Diagnosis | Research | Metastasis | Neovascularization | Drug therapy
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2012, Volume 366, Issue 7, pp. 610 - 618
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2005, Volume 353, Issue 1, pp. 33 - 45
Journal Article
Journal Article
American Journal of Hematology, ISSN 0361-8609, 01/2017, Volume 92, Issue 1, pp. 94 - 108
Disease overview Polycythemia Vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms respectively characterized by erythrocytosis and... 
ACUTE-LEUKEMIA | JAK2(V617F) MUTATION | MYELOFIBROSIS RESEARCH | LOW-DOSE ASPIRIN | LONG-TERM SURVIVAL | MYELOPROLIFERATIVE NEOPLASMS | CALRETICULIN MUTATIONS | DEFINED ESSENTIAL THROMBOCYTHEMIA | HEMATOLOGY | INTERFERON-ALPHA THERAPY | INTERNATIONAL WORKING GROUP | Primary Myelofibrosis - mortality | Humans | Polycythemia Vera - blood | Polycythemia Vera - genetics | Primary Myelofibrosis - pathology | Thrombocythemia, Essential - genetics | Calreticulin - genetics | Aspirin - administration & dosage | Erythropoietin - blood | Thrombocytosis - mortality | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Aspirin - therapeutic use | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Thrombocytosis - pathology | Thrombocythemia, Essential - drug therapy | Primary Myelofibrosis - diagnosis | Diagnosis, Differential | Risk Assessment | Interferon-alpha - therapeutic use | Janus Kinase 2 - genetics | Hydroxyurea - administration & dosage | Thrombocythemia, Essential - blood | Polycythemia Vera - diagnosis | Thrombocytosis - diagnosis | Interferon-alpha - administration & dosage | Receptors, Thrombopoietin - genetics | Thrombocythemia, Essential - diagnosis | Hydroxyurea - therapeutic use | Polycythemia Vera - drug therapy | Mutation | Erythropoietin | Polycythemia | Leukemia | Diagnosis | Tumor proteins | Thrombosis | Risk factors | Blood clot
Journal Article